CA2626016A1 - Pharmaceutical composition comprising at least one anticancer drug and at least one polymer - Google Patents

Pharmaceutical composition comprising at least one anticancer drug and at least one polymer Download PDF

Info

Publication number
CA2626016A1
CA2626016A1 CA002626016A CA2626016A CA2626016A1 CA 2626016 A1 CA2626016 A1 CA 2626016A1 CA 002626016 A CA002626016 A CA 002626016A CA 2626016 A CA2626016 A CA 2626016A CA 2626016 A1 CA2626016 A1 CA 2626016A1
Authority
CA
Canada
Prior art keywords
novel
cancer therapy
improved compositions
therapy according
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002626016A
Other languages
English (en)
French (fr)
Inventor
Amarjit Singh
Sarabjit Singh
Ajay K. Gupta
Mangesh M. Kulkarni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Panacea Biotec Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2626016A1 publication Critical patent/CA2626016A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002626016A 2005-10-21 2006-10-19 Pharmaceutical composition comprising at least one anticancer drug and at least one polymer Abandoned CA2626016A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN1327/MUM/2005 2005-10-21
IN1327MU2005 2005-10-21
IN1081/MUM/2006 2006-07-10
IN1081MU2006 2006-07-10
PCT/IN2006/000427 WO2007069272A2 (en) 2005-10-21 2006-10-19 Pharmaceutical composition comprising at least one anticancer drug and at least one polymer

Publications (1)

Publication Number Publication Date
CA2626016A1 true CA2626016A1 (en) 2007-06-21

Family

ID=38163340

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002626016A Abandoned CA2626016A1 (en) 2005-10-21 2006-10-19 Pharmaceutical composition comprising at least one anticancer drug and at least one polymer

Country Status (13)

Country Link
US (1) US20100166872A1 (cg-RX-API-DMAC7.html)
EP (1) EP1962906A4 (cg-RX-API-DMAC7.html)
JP (1) JP2009512682A (cg-RX-API-DMAC7.html)
AR (1) AR058130A1 (cg-RX-API-DMAC7.html)
AU (1) AU2006324872B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0617663A2 (cg-RX-API-DMAC7.html)
CA (1) CA2626016A1 (cg-RX-API-DMAC7.html)
CR (1) CR9989A (cg-RX-API-DMAC7.html)
EA (1) EA015781B1 (cg-RX-API-DMAC7.html)
IL (1) IL190882A0 (cg-RX-API-DMAC7.html)
MA (1) MA29946B1 (cg-RX-API-DMAC7.html)
RS (1) RS20080167A (cg-RX-API-DMAC7.html)
WO (1) WO2007069272A2 (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA016434B1 (ru) * 2007-12-24 2012-04-30 Сан Фарма Адвансед Ресёрч Компани Лимитед Нанодисперсия
US8871276B2 (en) 2008-02-11 2014-10-28 Technion Research And Development Foundation Ltd. Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents
US8865222B2 (en) 2008-02-11 2014-10-21 Technion Research And Development Foundation Ltd. Beta-casein assemblies for enrichment of food and beverages and methods of preparation thereof
WO2009101613A1 (en) 2008-02-11 2009-08-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents
US20110045092A1 (en) * 2008-02-11 2011-02-24 Livney Yoav D Casein particles encapsulating therapeutically active agents and uses thereof
GB0818747D0 (en) * 2008-10-13 2008-11-19 Univ Nottingham Biocompatible responsive materials
EP2266546A1 (en) 2009-06-08 2010-12-29 Advancell Advanced in Vitro Cell Technologies,S.A. Process for the preparation of colloidal systems for the delivery of active compounds
CN102802624A (zh) 2009-06-19 2012-11-28 太阳医药高级研发有限公司 药物的纳米分散体以及它的制备方法
WO2011017835A1 (en) * 2009-08-11 2011-02-17 Nanjing University Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
MX348668B (es) * 2009-09-21 2017-06-23 J W Pharmaceutical Corp * Nanopartículas de oxaliplatin y método para prepararlas.
CA2798180A1 (en) 2010-05-03 2011-11-10 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
CN103118669B (zh) * 2010-06-01 2016-01-13 盖斯特里希医药公司 口服药物治疗方法和组合物
WO2012058462A2 (en) * 2010-10-29 2012-05-03 Isis Pharmaceuticals, Inc. Combination therapy for the treatment of cancer
WO2012075414A2 (en) * 2010-12-02 2012-06-07 Ecosynthetix Ltd. Aptamer bioconjugate drug delivery device
JP6038881B2 (ja) 2011-04-20 2016-12-07 ザ・ユニバーシティ・オブ・シドニー 治療の方法及びそのために有用な剤
EP3238709B1 (en) 2011-04-28 2020-07-01 Platform Brightworks Two, Ltd. Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
WO2013124867A1 (en) * 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules
BR112014032346A2 (pt) 2012-06-26 2017-06-27 Del Mar Pharmaceuticals métodos para tratamento de malignidades resistentes ao inibidor de tirosina-quinase em pacientes com polimorfismos genéticos ou desregulações de ahi1 mutações empregando dianidrogalactitol, diacetildianidrogalactitol, dibromodulcitol, ou análogos ou derivados destes
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US10143700B2 (en) 2013-02-19 2018-12-04 Amrita Vishwa Vidyapeetham Nanoparticle formulations for delivering multiple therapeutic agents
JP2016519684A (ja) 2013-04-08 2016-07-07 デニス エム ブラウン 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
SMT201700442T1 (it) 2013-09-16 2017-11-15 Astrazeneca Ab Nanoparticelle polimeriche terapeutiche e metodi per preparare e usare le stesse
KR20150047336A (ko) 2013-10-24 2015-05-04 삼성전자주식회사 나노입자, 이를 제조하는 방법, 및 이의 용도
HUP1300646A2 (en) 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
CN103739672B (zh) * 2013-12-31 2015-06-10 威特曼生物科技（南京）有限公司 一种聚乙二醇修饰的抑制vegfr2酪氨酸激酶多肽及其应用
RU2591819C2 (ru) * 2014-03-03 2016-07-20 Закрытое акционерное общество "СКАЙ ЛТД" Способ получения фолликулярного белкового препарата и препарат, полученный данным способом
TW202337477A (zh) 2015-02-01 2023-10-01 美商錫羅斯製藥公司 用於病患口服之含砷高表面積冷凍乾燥組合物
WO2016141167A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Combination liposomal pharmaceutical formulations
US10736845B2 (en) 2015-03-03 2020-08-11 Cureport Inc. Dual loaded liposomal pharmaceutical formulations
CN106137969B (zh) * 2015-04-03 2020-05-15 四川科伦药物研究院有限公司 多西他赛白蛋白纳米粒药物组合物及其制备方法及应用
IL285928B2 (en) 2016-05-06 2025-06-01 Eagle Pharmaceuticals Inc Fulvestrant formulations and methods of their use
CN110753541A (zh) * 2017-04-24 2020-02-04 Zy治疗公司 用于体内递送的药物组合物、基本上不溶于水的药理学活性剂的制备方法
WO2019028457A2 (en) * 2017-08-04 2019-02-07 University Of Houston System FORMULATION OF NANOSUSPENSION OF DIETHYLSTILBESTROL INJECTABLE
CA3090303A1 (en) 2018-03-28 2019-10-03 Greenmark Biomedical Inc. Phosphate crosslinked starch nanoparticle and dental treatments
MX2021001276A (es) * 2018-07-31 2021-07-15 Microbion Corp Composiciones de bismuto-tiol y metodos para tratar heridas.
EP3829307A4 (en) 2018-07-31 2022-08-03 Microbion Corporation BISMUTH-THIOL COMPOSITIONS AND METHODS OF USE
FR3087650B1 (fr) * 2018-10-31 2021-01-29 Bio Even Flavine adenine dinucleotide (fad) pour son utilisation pour la prevention et/ou le traitement de cancer
CN114767879A (zh) * 2022-06-02 2022-07-22 平顶山学院 一种多西紫杉醇恶性肿瘤靶向微球及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2634397B2 (fr) * 1986-12-31 1991-04-19 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
US5766635A (en) * 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
WO1994026254A1 (en) * 1993-05-17 1994-11-24 The Liposome Company, Inc. Incorporation of taxol into liposomes and gels
SG113402A1 (en) * 1997-06-27 2005-08-29 American Bioscience Inc Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
WO2000071079A2 (en) * 1999-05-21 2000-11-30 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
WO2001049268A1 (en) * 2000-01-05 2001-07-12 Imarx Therapeutics, Inc. Pharmaceutical formulations for the delivery of drugs having low aqueous solubility
ITMI20001107A1 (it) * 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
EP1585504A4 (en) * 2002-11-06 2009-07-15 Azaya Therapeutics Inc Protein stabilized liposomal formulations of pharmaceutical active ingredients
KR20120068035A (ko) * 2002-12-09 2012-06-26 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법

Also Published As

Publication number Publication date
BRPI0617663A2 (pt) 2011-08-02
EA200801132A1 (ru) 2009-02-27
IL190882A0 (en) 2008-11-03
EP1962906A2 (en) 2008-09-03
EP1962906A4 (en) 2009-11-18
US20100166872A1 (en) 2010-07-01
WO2007069272A2 (en) 2007-06-21
AU2006324872B2 (en) 2012-03-08
RS20080167A (sr) 2009-07-15
JP2009512682A (ja) 2009-03-26
CR9989A (es) 2008-07-18
WO2007069272A3 (en) 2007-08-23
AU2006324872A1 (en) 2007-06-21
AR058130A1 (es) 2008-01-23
EA015781B1 (ru) 2011-12-30
MA29946B1 (fr) 2008-11-03

Similar Documents

Publication Publication Date Title
AU2006324872B2 (en) Pharmaceutical composition comprising at least one anticancer drug and at least one polymer
RU2451510C2 (ru) Композиции и способы получения слаборастворимых в воде лекарственных средств с увеличенной стабильностью
CA2371912C (en) Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US8137684B2 (en) Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6749868B1 (en) Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
ES2435944T3 (es) Nuevas formulaciones de agentes farmacológicos, métodos para su preparación y métodos para su uso
JP5117439B2 (ja) 蛋白質安定化した薬理学的活性薬剤、その製造方法およびその使用方法
US8853260B2 (en) Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
JP2019142924A (ja) 治療薬を徐放するための長時間循環性ナノ粒子
US20070128290A1 (en) Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20110293730A1 (en) Polylactide nanoparticles
CN101495148B (zh) 包括至少一种抗癌药和至少一种聚合物的药物组合物
EP3266450A1 (en) Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
HK1152882A (en) Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
HK1154511A (en) Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130805